Zydus begins supplying ZyCoV-D, first vaccine for age 12 and above in India

Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India from its newly commissioned state-of-the-art, Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Changodar, Ahmedabad. The company is also planning to make the vaccine available in the private market.

Ahmedabad (Gujarat): Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India from its newly commissioned state-of-the-art, Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Changodar, Ahmedabad. The company is also planning to make the vaccine available in the private market.

ZyCoV-D is a three-dose vaccine administered intradermally using the painless PharmaJet needle-free system, Tropis, on day 0, day 28 and day 56. The vaccine will be priced at Rs 265 per dose and the applicator is being offered at Rs 93 per dose excluding GST. ZyCoV-D is the first vaccine approved by the Drug Controller General of India (DCGI) for inoculation of those in the age group of 12 and above. According to official sources, the Central Government has already placed an order of 1 crore doses of ZyCoV-D with Zydus Cadila.

Zydus VTEC manufactures the drug substance for the needle-free DNA Plasmid vaccine, ZyCoV-D. The manufacturing process and in-process material transfers within the plant are automated. Zydus has also entered into a definitive agreement with Shilpa Medicare Limited, a contract manufacturing organization to produce mutually agreeable doses of ZyCoV-D. The company also entered into an agreement with Enzychem Lifesciences of the Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine.